Brief: Heidelberg Pharma FY Net Loss Widens To EUR -26.1 Mln

Heidelberg Pharma AG

24/03/2022 06:14

March 24 (Reuters) - HEIDELBERG PHARMA AG  HPHA.DE :
    * FY EPS LOSS 0.80 EUR VERSUS 0.61 EUR LOSS YEAR AGO
    * FINANCIAL FIGURES IN LINE WITH ADJUSTED FORECAST
    * FY SALES REVENUE OF EUR 1.7 MILLION (PREVIOUS YEAR: EUR
8.5
MILLION)
    * FINANCIAL FIGURES IN LINE WITH ADJUSTED FORECAST
    * FY NET LOSS OF EUR -26.1 MILLION (PREVIOUS YEAR: EUR -18.4
MILLION)
    * EXPECTS HEIDELBERG PHARMA GROUP TO GENERATE BETWEEN EUR
7.5
MILLION AND EUR 9.5 MILLION IN REVENUE AND OTHER INCOME IN 2022
FISCAL YEAR (2021: EUR 2.3 MILLION)
    * SALES REVENUE IS EXPECTED TO INCREASE DUE TO LICENSING
AGREEMENT
WITH HUADONG
    * EARNINGS BEFORE INTEREST AND TAXES (EBIT) IN 2022 FISCAL
YEAR
ARE EXPECTED TO BE BETWEEN EUR -32.5 MILLION AND EUR -36.5
MILLION (2021: EUR -25.6 MILLION)
    * FINANCING REQUIREMENTS IN 2022 FISCAL YEAR FOR HEIDELBERG
PHARMA
AG'S BUSINESS OPERATIONS ARE EXPECTED TO INCREASE COMPARED TO
2021
    * OUTLOOK 2022: EXPECTS HEIDELBERG PHARMA GROUP TO GENERATE
BETWEEN EUR 7.5 MILLION AND EUR 9.5 MILLION IN REVENUE AND OTHER
INCOME IN 2022 FISCAL YEAR (2021: EUR 2.3 MILLION)
    * OUTLOOK 2022: EARNINGS BEFORE INTEREST AND TAXES (EBIT) IN
2022
FISCAL YEAR ARE EXPECTED TO BE BETWEEN EUR -32.5 MILLION AND EUR
-36.5 MILLION (2021: EUR -25.6 MILLION)
    * FUNDS USED ARE EXPECTED TO BE IN RANGE OF EUR 33.0 MILLION
TO
EUR 37.0 MILLION IN 2022

Source text for Eikon:  ID:nEQc0ZrRCa 
Further company coverage:  HPHA.DE 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))